Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Ron Dior who wrote (1079)	5/21/1998 11:48:00 PM
From: Tom Hua	Read Replies (1) \| Respond to of 2135

Ron, there's an article in next week's Business Week about the progress of cancer research. Three companies and their drugs were mentioned: Genetech, Centocor, and MedImmune. No EntreMed. Regards, Tom

To: Ron Dior who wrote (1079)	5/22/1998 8:46:00 PM
From: Nero	Read Replies (1) \| Respond to of 2135

Ron, ENMD, like many other biotechs, has not turned a profit. How do you determine fair market value on an unprofitable company? The market cap at 31 is $384 million. Why do you think it is worth $12 a share? Why not $2? The marketplace believes it is worth $31 today. That will certainly change -- and the change will be based on the marketplace's perception of ENMD's future prospects. The NCI seems to think that angiostatin and endostatin are somewhat special, as illustrated by the fast track that NCI is putting their reputation -- and money -- behind. By all means, short ENMD if you can find the shares to borrow. I'd rather put my money on Judah Folkman's research. You may put some money in your pocket. Maybe, maybe not. Good luck. nero